Today Gemphire Therapeutics Inc. (GEMP) Stock Reaches All-Time Low

The stock of Gemphire Therapeutics Inc. (NASDAQ:GEMP) reached all time low today, Aug, 15 and still has $0.51 target or 8.00 % below today’s $0.55 share price. This indicates more downside for the $8.18 million company. This technical setup was reported by Barchart.com. If the $0.51 PT is reached, the company will be worth $654,400 less.
Trading stocks at an all time low is not easy. Stock at an all time low usually experience even more downside due to very negative fundament. Even thought the pullback rate is high, shorting is not an easy job because the risk of being wrong is big and the risk-reward ratio is always worse than if trading lon only.

The stock decreased 13.74% or $0.0876 during the last trading session, reaching $0.55. About 173,765 shares traded. Gemphire Therapeutics Inc. (NASDAQ:GEMP) has declined 91.55% since August 15, 2018 and is downtrending. It has underperformed by 91.55% the S&P500.

More notable recent Gemphire Therapeutics Inc. (NASDAQ:GEMP) news were published by: Nasdaq.com which released: “Gemphire Therapeutics Reports Second Quarter 2019 Financial Results and Provides Corporate Update – Nasdaq” on August 09, 2019, also Finance.Yahoo.com with their article: “Gemphire Therapeutics Inc.’s (NASDAQ:GEMP) Path To Profitability – Yahoo Finance” published on June 27, 2019, Benzinga.com published: “50 Stocks Moving In Thursday’s Mid-Day Session – Benzinga” on July 25, 2019. More interesting news about Gemphire Therapeutics Inc. (NASDAQ:GEMP) were released by: Benzinga.com and their article: “31 Healthcare Stocks Moving In Today’s Pre-Market Session – Benzinga” published on August 09, 2019 as well as Benzinga.com‘s news article titled: “64 Biggest Movers From Yesterday – Benzinga” with publication date: July 26, 2019.

Gemphire Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of dyslipidemia cardiovascular disease and nonalcoholic fatty liver disease/non-alcoholic steatohepatitis . The company has market cap of $8.18 million. It is developing gemcabene (CI-1027), an oral therapy for patients who are unable to achieve normal levels of LDL-C or triglycerides with currently approved therapies, primarily statin therapy and for those patients who present with NASH. It currently has negative earnings.

Gemphire Therapeutics Inc. (NASDAQ:GEMP) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.